Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Endoscopy of Esophageal Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced esophageal carcinoma (cT1b-4a N0-3 M0) in multi-disciplinary esophageal oncology meeting agreed on long course neoadjuvant chemoradiotherapy, followed by esophagectomy;~* Age ≥ 18 years;~* Written informed consent.~Exclusion Criteria:~* Patients with psychological diseases or medical issues who are not able to sign informed consent form;~  * Concurrent uncontrolled medical conditions;~ * Pregnancy or breast feeding. A negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause);~ * Irradical endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of primary tumor prior to start of neoadjuvant chemoradiotherapy~ * Received a different investigational drug within 30 days prior to the dose of bevacizumab-800CW;~ * History of infusion reactions to bevacizumab or other monoclonal antibodies;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NIR endoscopy with 4.5 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.
- NIR endoscopy with 10 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.
- NIR endoscopy with 25 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.

Based on this trial design, predict the completion outcome and termination type (if applicable).